378 related articles for article (PubMed ID: 23956442)
1. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Omae K; Kondo T; Kennoki T; Takagi T; Iizuka J; Kobayashi H; Hashimoto Y; Tanabe K
Int J Clin Oncol; 2016 Feb; 21(1):126-32. PubMed ID: 26163345
[TBL] [Abstract][Full Text] [Related]
4. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Zhang Y; Li Y; Cai Y; Wang K; Li H
Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
Sil A; Das NK
Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
12. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
13. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
[TBL] [Abstract][Full Text] [Related]
14. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
15. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T;
Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
20. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]